Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035 Lisbon, Portugal.
Luís Costa Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Int J Mol Sci. 2023 Aug 29;24(17):13385. doi: 10.3390/ijms241713385.
Precision oncology is the ultimate goal of cancer treatment, i.e., to treat cancer and only cancer, leaving all the remaining cells and tissues as intact as possible. Classical chemotherapy and radiotherapy, however, are still effective in many patients with cancer by effectively inducing apoptosis of cancer cells. Cancer cells might resist apoptosis via the anti-apoptotic effects of the inhibitor of apoptosis proteins. Recently, the inhibitors of those proteins have been developed with the goal of enhancing the cytotoxic effects of chemotherapy and radiotherapy, and one of them, xevinapant, has already demonstrated effectiveness in a phase II clinical trial. This class of drugs represents an example of synergism between classical cytotoxic chemo- and radiotherapy and new targeted therapy.
精准肿瘤学是癌症治疗的终极目标,即只治疗癌症,同时尽可能保持所有剩余的细胞和组织完好无损。然而,经典的化疗和放疗仍然可以通过有效诱导癌细胞凋亡,在许多癌症患者中发挥作用。癌细胞可能通过凋亡抑制蛋白的抗凋亡作用来抵抗凋亡。最近,已经开发出这些蛋白的抑制剂,目的是增强化疗和放疗的细胞毒性作用,其中一种名为 xevinapant 的药物已经在 II 期临床试验中证明了其有效性。这类药物代表了经典细胞毒化疗和放疗与新的靶向治疗之间协同作用的一个例子。